GLINT: GlucoCEST in neoplastic tumors at 3 T-clinical results of GlucoCEST in gliomas.
MAGMA
; 35(1): 77-85, 2022 Feb.
Article
em En
| MEDLINE
| ID: mdl-34890014
OBJECTIVE: Clinical relevance of dynamic glucose enhanced (DGE) chemical exchange saturation transfer (CEST) imaging has mostly been demonstrated at ultra-high field (UHF) due to low effect size. Results of a cohort study at clinical field strength are shown herein. MATERIALS AND METHODS: Motion and field inhomogeneity corrected T1ρ-based DGE (DGEâ´) images were acquired before, during and after a D-glucose injection with 6.3 s temporal resolution to detect accumulation in the brain. Six glioma patients with clear blood-brain barrier (BBB) leakage, two glioma patients with suspected BBB leakage, and three glioma patients without BBB leakage were scanned at 3 T. RESULTS: In high-grade gliomas with BBB leakage, D-glucose uptake could be detected in the gadolinium (Gd) enhancing region as well as in the tumor necrosis with a maximum increase of ∆DGEâ´ around 0.25%, whereas unaffected white matter did not show any significant DGEâ´ increase. Glioma patients without Gd enhancement showed no detectable DGEâ´ effect within the tumor. CONCLUSION: First application of DGEâ´ in a patient cohort shows an association between BBB leakage and DGE signal irrespective of the tumor grade. This indicates that glucoCEST corresponds more to the disruptions of BBB with Gd uptake than to the molecular tumor profile or tumor grading.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Encefálicas
/
Glioma
Tipo de estudo:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article